Hira Rizvi

21.4k total citations · 3 hit papers
64 papers, 3.5k citations indexed

About

Hira Rizvi is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hira Rizvi has authored 64 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 49 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 16 papers in Cancer Research. Recurrent topics in Hira Rizvi's work include Lung Cancer Treatments and Mutations (38 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Cancer Genomics and Diagnostics (16 papers). Hira Rizvi is often cited by papers focused on Lung Cancer Treatments and Mutations (38 papers), Cancer Immunotherapy and Biomarkers (34 papers) and Cancer Genomics and Diagnostics (16 papers). Hira Rizvi collaborates with scholars based in United States, Spain and France. Hira Rizvi's co-authors include Matthew D. Hellmann, Kathryn C. Arbour, Andrew J. Plodkowski, Gregory J. Riely, Darragh Halpenny, Mark G. Kris, Jamie E. Chaft, Niamh M. Long, Ai Ni and Helena A. Yu and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Hira Rizvi

62 papers receiving 3.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non–Small-Cell Lung Cancer

2018 712 citations Kathryn C. Arbour, Niamh M. Long et al. profile →
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer

2018 631 citations Lisa Derosa, Matthew D. Hellmann et al. Annals of Oncology profile →
Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib

2019 271 citations Adam J. Schoenfeld, Kathryn C. Arbour et al. Annals of Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hira Rizvi United States	23	2.9k	1.7k	683	508	426	64	3.5k
Mehmet Altan United States	24	2.1k 0.7×	885 0.5×	364 0.5×	559 1.1×	200 0.5×	121	2.5k
William J. Geese United States	20	2.5k 0.9×	1.4k 0.8×	481 0.7×	619 1.2×	455 1.1×	43	3.0k
Osama E. Rahma United States	28	2.1k 0.7×	520 0.3×	485 0.7×	1.0k 2.0×	310 0.7×	113	2.9k
Asim Amin United States	27	2.6k 0.9×	1.1k 0.6×	905 1.3×	1.1k 2.2×	431 1.0×	73	3.4k
Alejandro Navarro Spain	19	2.0k 0.7×	1.3k 0.8×	669 1.0×	304 0.6×	305 0.7×	110	2.6k
Leila Khoja United Kingdom	20	1.7k 0.6×	612 0.4×	416 0.6×	403 0.8×	388 0.9×	50	2.1k
Kristen A. Marrone United States	16	1.5k 0.5×	761 0.4×	458 0.7×	418 0.8×	190 0.4×	74	2.0k
Akin Atmaca Germany	24	2.2k 0.8×	1.4k 0.8×	845 1.2×	505 1.0×	304 0.7×	61	3.3k
Feng‐Hua Wang China	31	1.5k 0.5×	861 0.5×	872 1.3×	232 0.5×	822 1.9×	126	2.9k
Steven Limentani United States	25	2.0k 0.7×	800 0.5×	1.3k 1.9×	142 0.3×	380 0.9×	60	3.4k

Countries citing papers authored by Hira Rizvi

Since Specialization

Citations

This map shows the geographic impact of Hira Rizvi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hira Rizvi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hira Rizvi more than expected).

Fields of papers citing papers by Hira Rizvi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hira Rizvi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hira Rizvi. The network helps show where Hira Rizvi may publish in the future.

Co-authorship network of co-authors of Hira Rizvi

This figure shows the co-authorship network connecting the top 25 collaborators of Hira Rizvi. A scholar is included among the top collaborators of Hira Rizvi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hira Rizvi. Hira Rizvi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schoenfeld, Adam J., Hira Rizvi, Danish Memon, et al.. (2022). Systemic and Oligo-Acquired Resistance to PD-(L)1 Blockade in Lung Cancer. Clinical Cancer Research. 28(17). 3797–3803. 31 indexed citations

Luo, Jia, Song Wu, Hira Rizvi, et al.. (2022). Deciphering radiological stable disease to immune checkpoint inhibitors. Annals of Oncology. 33(8). 824–835. 24 indexed citations

Choudhury, Noura J., Adam J. Schoenfeld, Jessica Flynn, et al.. (2021). Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions. Clinical Cancer Research. 27(10). 2920–2927. 47 indexed citations

Li, Chuan, Wen‐Yang Lin, Hira Rizvi, et al.. (2021). Quantitative In Vivo Analyses Reveal a Complex Pharmacogenomic Landscape in Lung Adenocarcinoma. Cancer Research. 81(17). 4570–4580. 10 indexed citations

Beattie, Jason, Hira Rizvi, Jia Luo, et al.. (2021). Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade. Journal for ImmunoTherapy of Cancer. 9(2). e001884–e001884. 39 indexed citations

Arbour, Kathryn C., Hira Rizvi, Andrew J. Plodkowski, et al.. (2021). Treatment Outcomes and Clinical Characteristics of Patients with KRAS-G12C–Mutant Non–Small Cell Lung Cancer. Clinical Cancer Research. 27(8). 2209–2215. 82 indexed citations

Luo, Jia, Jason Beattie, Hira Rizvi, et al.. (2021). Beyond Steroids: Immunosuppressants in Steroid-Refractory or Resistant Immune-Related Adverse Events. Journal of Thoracic Oncology. 16(10). 1759–1764. 74 indexed citations

Pagano, Andrew, Andrew J. Plodkowski, Jeffrey Girshman, et al.. (2021). Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. Lung Cancer. 161. 60–67. 2 indexed citations

Alessi, Joao V., Biagio Ricciuti, Fangxin Hong, et al.. (2020). Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status. Journal for ImmunoTherapy of Cancer. 8(2). e001007–e001007. 40 indexed citations

10.

Schoenfeld, Adam J., Joseph Montecalvo, Azadeh Namakydoust, et al.. (2020). A07 The Genomic Landscape of SMARCA4 Alterations and Association with Patient Outcomes in Lung Cancer. Journal of Thoracic Oncology. 15(2). S14–S14. 1 indexed citations

11.

Hu‐Lieskovan, Siwen, Aaron Lisberg, Jesse M. Zaretsky, et al.. (2019). Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research. 25(16). 5061–5068. 56 indexed citations

12.

Schoenfeld, Adam J., Kathryn C. Arbour, Hira Rizvi, et al.. (2019). Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Annals of Oncology. 30(5). 839–844. 271 indexed citations breakdown →

13.

Offin, Michael, Joseph M. Chan, Megan Tenet, et al.. (2019). Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes. Journal of Thoracic Oncology. 14(10). 1784–1793. 257 indexed citations

14.

Offin, Michael, Hira Rizvi, Megan Tenet, et al.. (2018). Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR -Mutant Lung Cancers. Clinical Cancer Research. 25(3). 1063–1069. 230 indexed citations

15.

Santini, Fernando C., Hira Rizvi, Andrew J. Plodkowski, et al.. (2018). Safety and Efficacy of Re-treating with Immunotherapy after Immune-Related Adverse Events in Patients with NSCLC. Cancer Immunology Research. 6(9). 1093–1099. 263 indexed citations

16.

Vokes, Natalie I., Anika E. Adeni, Renato Umeton, et al.. (2018). MA19.01 Efficacy and Genomic Correlates of Response to Anti-PD1/PD-L1 Blockade in Non-Small Cell Lung Cancers Harboring Targetable Oncogenes. Journal of Thoracic Oncology. 13(10). S422–S422. 9 indexed citations

17.

Arbour, Kathryn C., Andrew J. Plodkowski, Hira Rizvi, et al.. (2018). MA19.09 Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L)1 Blockade in Patients with NSCLC Despite High TMB. Journal of Thoracic Oncology. 13(10). S424–S424. 24 indexed citations

18.

Gainor, Justin F., Sasha Kravets, S. Khosrowjerdi, et al.. (2018). MA04.05 Outcomes in NSCLC Patients Treated with First-Line Pembrolizumab and a PD-L1 TPS of 50-74% vs 75-100% or 50-89% vs 90-100%. Journal of Thoracic Oncology. 13(10). S367–S368. 9 indexed citations

19.

Derosa, Lisa, Matthew D. Hellmann, Marco Spaziano, et al.. (2018). Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. Annals of Oncology. 29(6). 1437–1444. 631 indexed citations breakdown →

20.

Rizvi, Hira, et al.. (1987). Screening of higher plants for antibacterial activity. Pakistan journal of scientific and industrial research. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact